Skip to main content
TipRanks
Go Ultimate75% OFF

Theranexus SA (ALTHX) AI Stock Analysis

7 Followers
FR:ALTHX

Theranexus SA

(Paris:ALTHX)

Select Model
Rating:41Neutral
Price Target:EUR 3.00▼(-8.26% Downside)
Action:reiterated
Date:09/10/26

The overall score is very low, driven primarily by the company's weak financial performance, including zero revenue and ongoing losses. Bearish technical momentum and a negative P/E ratio further weigh on the assessment. The key mitigating factor is the improving cash flow trend, which suggests a path toward breakeven, but this is not yet sufficient to offset the significant fundamental risks.

Positive Factors
Moderated DebtDebt has moderated from prior peaks and remained around €2.9m recently, which somewhat reduces leverage pressure compared with earlier periods. This improvement does not remove balance-sheet risk, but it may provide modestly greater financial flexibility while the company advances its clinical pipeline.
Negative Factors
Zero RevenueThe complete revenue drop to zero in 2025 highlights substantial commercialization and execution risk for a clinical-stage company. Without recurring product revenue, Theranexus has limited internal funding capacity and remains dependent on successfully advancing programs or securing external capital.

Theranexus SA (ALTHX) vs. iShares MSCI France ETF (EWQ)

-25%0%25%50%75%100%125%150%175%FR:ALTHX+94.64%EWQ+2.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 47.93M
Dividend Yield
―
Average Volume (3M)
66.63K
Price to Earnings (P/E)
-34.3
Beta (1Y)
0.22
Revenue Growth
―
EPS Growth
54.40%
Country
France
Employees
12
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Theranexus SA Business Overview & Revenue Model

Company Description

Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical evaluation f...

How the Company Makes Money

Theranexus is a clinical-stage biopharmaceutical company; detailed, consistently disclosed product-sales revenue information is not available here, and the company is not generally expected to generate meaningful recurring revenue from commercial dru...

Theranexus SA Financial Statement Overview

Summary

Financial health is precarious. The income statement reflects zero revenue and substantial operating losses, scoring 20. The balance sheet shows improvement with positive equity but remains fragile with elevated debt-to-equity, scoring 35. Cash flow is trending positively with a significantly reduced burn rate, scoring 40. Overall, the company is high-risk with a thin financial cushion.

Income Statement

20Very Negative

Balance Sheet

35Negative

Cash Flow

40Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.26M02.28M296.33K414.90K602
Gross Profit1.03M-108.60K-333.55K-4.64M82.90K-8.82M
EBITDA-9.76M-10.12M-2.53M-7.39M-5.93M-8.67M
Net Income-2.03M-3.00M-1.77M-6.83M-6.57M-8.15M
Balance Sheet
Total Assets22.63M10.54M3.74M7.24M12.05M16.89M
Cash, Cash Equivalents and Short-Term Investments17.45M7.77M966.59K4.90M9.11M12.53M
Total Debt2.59M2.88M2.87M3.64M4.89M5.33M
Total Liabilities19.66M7.64M5.40M5.02M6.33M6.71M
Stockholders Equity2.98M1.99M-1.66M2.22M5.73M10.18M
Cash Flow
Free Cash Flow8.86M-939.81K-3.40M-6.40M-5.41M-6.40M
Operating Cash Flow9.07M-883.76K-3.37M-6.36M-5.37M-6.25M
Investing Cash Flow-319.59K-168.23K77.04K-61.11K323.53K-150.62K
Financing Cash Flow7.74M7.85M-646.42K2.22M1.63M7.71M

Theranexus SA Technical Analysis

Technical Analysis SentimentNegative
Last Price3.27

Price Trends

50DMA3.32Positive
100DMA3.66Negative
200DMA3.47Negative

Market Momentum

MACD0.02Negative
RSI48.85Neutral
STOCH72.59Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTHX, the sentiment is Negative. The current price of 3.27 is below the 20-day moving average (MA) of 3.34, below the 50-day MA of 3.32, and below the 200-day MA of 3.47, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 48.85 is Neutral, neither overbought nor oversold. The STOCH value of 72.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALTHX.

Theranexus SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

FR:ALTHX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FR:MEDCLFR:MEDCL61NeutralEUR 1.04B-31.67――-23.21%-50.69%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:ABFR:AB45NeutralEUR 60.33M-7.7627.28%―12.66%44.01%
FR:SIGHTFR:SIGHT43NeutralEUR 18.44M-1.0352.39%―-610.31%43.88%
FR:ALSENFR:ALSEN41NeutralEUR 85.34M-1.99-54.15%――6.26%
FR:ALTHXFR:ALTHX41NeutralEUR 47.93M-34.26-81.82%――54.40%
FR:ALINSFR:ALINS21UnderperformEUR 10.77M-0.76148.60%―-24.18%-120.44%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%FR:ALTHXFR:SIGHTFR:ABFR:ALSENFR:ALINSFR:MEDCLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FR:ALTHX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FR:ALTHXTheranexus SA3.271.5286.86%
FR:SIGHTGenSight Biologics0.08-0.02-23.00%
FR:ABAb Science0.58-0.56-49.04%
FR:ALSENSensorion SAS8.26-8.64-51.14%
FR:ALINSIntrasense SA0.20-0.05-20.62%
FR:MEDCLMedinCell SA28.48-1.88-6.19%

Theranexus SA Corporate Events

THX Pharma Nears Break-Even as Rare Disease Pivot Gains Traction

Sep 29, 2026

THX Pharma reported a near break-even performance for the first half of 2026, underpinned by €3.24 million in revenue and a sharply reduced net loss of €0.1 million compared with €1.07 million a year earlier. The improvement stems largely from recogn...

THX Pharma Secures Long-Term European Patent Protection for Batten-1

Sep 9, 2026

THX Pharma and the Beyond Batten Disease Foundation have secured a key European patent protecting the use of miglustat, the active ingredient in Batten-1, for treating juvenile Batten disease. Jointly owned by BBDF, Baylor College of Medicine and Car...

THX Pharma Advances Batten-1 With Global Phase 3 Trial Filings for Juvenile Batten Disease

Sep 1, 2026

THX Pharma (Theranexus), together with Beyond Batten Disease Foundation and Biocodex, has submitted regulatory applications in the United States, United Kingdom and several European countries to launch an international phase 3 trial of Batten-1, an o...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 10, 2026